the MCCE vs EGD Trial

NANot yet recruitingINTERVENTIONAL
Enrollment

238

Participants

Timeline

Start Date

September 24, 2025

Primary Completion Date

September 24, 2027

Study Completion Date

November 24, 2027

Conditions
AnaemiaAcute Coronary Syndrome
Interventions
PROCEDURE

Magnetically Controlled Capsule Endoscopy (MCCE)

. The MCCE used in this study is the magnetically controlled capsule endoscopy (MCE, AnPx USA) which is a capsule measuring 28x12mm, and contains a permanent magnet inside its dome. Images are captured and recorded at 2 frames/s

PROCEDURE

Esophageal-gastro-Duodenoscopy (EGD)

Esophageal-gastro-Duodenoscopy (EGD) is commonly performed to look for source of bleeding in patients with anaemia. However, from our own analysis and from retrospective studies of EGD in patients with ACS, EGD finding was normal or non-significant in 20-80% patients14-16. Moreover, EGD was associated with non-negligible periprocedural risks in patients with ACS, including death directly attributed to EGD (9.1%; 95% CI 7.6-10.9%), hypotension (24.1%; 95% CI 17.0-32.9%), arrhythmias (8.3%; 95% CI 4.5-15.1%) and recurrent ACS (6.5%; 95% CI 3.2-12.8%)

Trial Locations (1)

0000

Prince of Wales Hospital, Hong Kong

All Listed Sponsors
collaborator

Health and Medical Research Fund

OTHER_GOV

lead

Chinese University of Hong Kong

OTHER

NCT07004530 - the MCCE vs EGD Trial | Biotech Hunter | Biotech Hunter